{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:05:37Z","timestamp":1793387137766,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jiac.2025.102756","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T14:45:45Z","timestamp":1750171545000},"page":"102756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Examining the safety and efficacy of Azithromycin in Cystic fibrosis: A systematic review and Meta-analysis"],"prefix":"10.1016","volume":"31","author":[{"given":"Aya Abd","family":"Elmegeed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6126-1288","authenticated-orcid":false,"given":"Mariam A.","family":"Lotfy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3526-7076","authenticated-orcid":false,"given":"Ahmed R.","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esraa S.F.","family":"Sudan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6434-7252","authenticated-orcid":false,"given":"Rania M.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6029-7858","authenticated-orcid":false,"given":"Naglaa M.","family":"Marzuuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel-Karim","family":"Aljebeai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad M.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Arman","family":"Rabbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pojsakorn","family":"Danpanichkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5941-9717","authenticated-orcid":false,"given":"Abdelrahman M.","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2025.102756_bib1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fphar.2013.00040","article-title":"Genetic influences on cystic fibrosis lung disease severity","volume":"4","author":"Weiler","year":"2013","journal-title":"Front Pharmacol"},{"issue":"7632","key":"10.1016\/j.jiac.2025.102756_bib2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/bmj.39391.713229.AD","article-title":"Cystic fibrosis","volume":"335","author":"Davies","year":"2007","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jiac.2025.102756_bib3","first-page":"690","article-title":"Novel therapeutic approaches for the management of cystic fibrosis","volume":"15","author":"Jaques","year":"2020","journal-title":"Multidiscip Respir Med [Internet]"},{"issue":"2","key":"10.1016\/j.jiac.2025.102756_bib4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jcf.2015.11.012","article-title":"An evaluation strategy for potential QTc prolongation with chronic azithromycin therapy in cystic fibrosis","volume":"15","author":"Lenehan","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jiac.2025.102756_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2016.05.025","article-title":"Long-term effects of azithromycin in patients with cystic fibrosis","volume":"117","author":"Samson","year":"2016","journal-title":"Respir Med [Internet]"},{"issue":"5","key":"10.1016\/j.jiac.2025.102756_bib6","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1183\/09031936.04.00084304","article-title":"Azithromycin for cystic fibrosis","volume":"24","author":"Southern","year":"2004","journal-title":"Eur Respir J [Internet]"},{"issue":"1","key":"10.1016\/j.jiac.2025.102756_bib7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.24953\/turkjped.2016.01.005","article-title":"Long term azithromycin therapy in patients with cystic fibrosis","volume":"58","author":"Emiralio\u011flu","year":"2016","journal-title":"Turk J Pediatr [Internet]"},{"issue":"1","key":"10.1016\/j.jiac.2025.102756_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2009.09.001","article-title":"Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial","volume":"9","author":"Kabra","year":"2010","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jiac.2025.102756_bib9","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ppul.21601","article-title":"Open\u2010label, follow\u2010on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa","volume":"47","author":"Saiman","year":"2012","journal-title":"Pediatr Pulmonol [Internet]"},{"issue":"5","key":"10.1016\/j.jiac.2025.102756_bib10","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1378\/chest.12-0628","article-title":"Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa","volume":"142","author":"Ratjen","year":"2012","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.jiac.2025.102756_bib11","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.rmed.2008.03.009","article-title":"Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection","volume":"102","author":"Steinkamp","year":"2008","journal-title":"Respir Med [Internet]"},{"issue":"8","key":"10.1016\/j.jiac.2025.102756_bib12","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-2600(22)00165-5","article-title":"The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial","volume":"10","author":"Stick","year":"2022","journal-title":"Lancet Respir Med [Internet]"},{"issue":"3","key":"10.1016\/j.jiac.2025.102756_bib13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/thorax.57.3.212","article-title":"Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial","volume":"57","author":"Wolter","year":"2002","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.jiac.2025.102756_bib14","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1164\/rccm.201802-0215OC","article-title":"Azithromycin for early Pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial","volume":"198","author":"Mayer-Hamblett","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jiac.2025.102756_bib15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1183\/09031936.00163306","article-title":"Daily versus weekly azithromycin in cystic fibrosis patients","volume":"30","author":"McCormack","year":"2007","journal-title":"Eur Respir J [Internet]"},{"issue":"9338","key":"10.1016\/j.jiac.2025.102756_bib16","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0140-6736(02)11081-6","article-title":"Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial","volume":"360","author":"Equi","year":"2002","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jiac.2025.102756_bib17","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thx.2005.057950","article-title":"Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial","volume":"61","author":"Clement","year":"2006","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.jiac.2025.102756_bib18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/thoraxjnl-2021-217782","article-title":"Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial","volume":"77","author":"Nichols","year":"2022","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.jiac.2025.102756_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jcf.2012.05.010","article-title":"A retrospective analysis of the impact of azithromycin maintenance therapy on adults attending a UK cystic fibrosis clinic","volume":"12","author":"Fleet","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jiac.2025.102756_bib20","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1164\/rccm.201906-1206OC","article-title":"Pulmonary outcomes associated with long-term azithromycin therapy in cystic fibrosis","volume":"201","author":"Nichols","year":"2020","journal-title":"Am J Respir Crit Care Med [Internet]"},{"issue":"6","key":"10.1016\/j.jiac.2025.102756_bib21","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jcf.2022.02.015","article-title":"Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas","volume":"21","author":"Pittman","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jiac.2025.102756_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jcf.2004.09.001","article-title":"Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study","volume":"4","author":"Hansen","year":"2005","journal-title":"J Cyst Fibros [Internet]"},{"issue":"13","key":"10.1016\/j.jiac.2025.102756_bib23","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.jiac.2025.102756_bib24","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.2010.563","article-title":"Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"303","author":"Saiman","year":"2010","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jiac.2025.102756_bib25","article-title":"Macrolide antibiotics (including azithromycin) for cystic fibrosis","volume":"2","author":"Southern","year":"2024","journal-title":"Cochrane database Syst Rev [Internet]"},{"issue":"9100","key":"10.1016\/j.jiac.2025.102756_bib26","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0140-6736(05)78360-4","article-title":"Long-term azithromycin may improve lung function in children with cystic fibrosis","volume":"351","author":"Jaff\u00e9","year":"1998","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jiac.2025.102756_bib27","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/jac\/dkr040","article-title":"Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review","volume":"66","author":"Cai","year":"2011","journal-title":"J Antimicrob Chemother [Internet]"},{"issue":"6","key":"10.1016\/j.jiac.2025.102756_bib28","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.pupt.2009.03.002","article-title":"Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis","volume":"22","author":"Florescu","year":"2009","journal-title":"Pulm Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.jiac.2025.102756_bib29","article-title":"Macrolide antibiotics for cystic fibrosis","volume":"11","author":"Southern","year":"2012","journal-title":"Cochrane database Syst Rev [Internet]"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25001539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25001539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:17:10Z","timestamp":1752711430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25001539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1341321X25001539"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102756","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Examining the safety and efficacy of Azithromycin in Cystic fibrosis: A systematic review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102756","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102756"}}